SCHEMBL5828079

SCHEMBL5828079

CC(=O)OC[C@H]1O[C@@H](n2c3ncccc3c3c4c(c5c6ccccc6[nH]c5c32)C(=O)N(COCc2ccccc2)C4=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 1/20 0.40
PRKCA P17252 5/20 0.39
ALDH1A1 P00352 5/20 0.38
PARP1 P09874 1/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
AKT1 P31749 1/20 0.38
PTK2 Q05397 1/20 0.38
THRB P10828 1/20 0.38
HIF1A Q16665 1/20 0.38
KDM4E B2RXH2 3/20 0.37
HPGD P15428 3/20 0.37
MAPT P10636 2/20 0.37
TSHR P16473 1/20 0.36
TGM2 P21980 1/20 0.36
NQO1 P15559 1/20 0.35
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA9 Q16790 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5828937 1.00 GALR3 (0.40) GALR3PRKCAALDH1A1PARP1LMNA
SCHEMBL5828686 0.94 GALR3 (0.40) GALR3PRKCAALDH1A1PARP1LMNA
SCHEMBL5827642 0.91 PRKCA (0.43) GALR3PRKCAALDH1A1PARP1LMNA
SCHEMBL5827662 0.89 PRKCA (0.49) GALR3PRKCAALDH1A1PARP1LMNA
SCHEMBL5828420 0.84 LMNA (0.43) GALR3PRKCAALDH1A1LMNASMN1; SMN2
SCHEMBL8769342 0.83 GALR3 (0.40) GALR3PRKCAALDH1A1LMNASMN1; SMN2
SCHEMBL8769931 0.83 GALR3 (0.40) GALR3PRKCAALDH1A1LMNASMN1; SMN2
SCHEMBL9083954 0.82 GALR3 (0.39) GALR3PRKCAALDH1A1LMNASMN1; SMN2
SCHEMBL5828121 0.82 LMNA (0.46) GALR3PRKCAALDH1A1LMNASMN1; SMN2
SCHEMBL5828918 0.82 PRKCA (0.41) GALR3PRKCAALDH1A1PARP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001906-B2 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives LES LABORATOIRES SERVIER (FR) 2006-02-21 US disclosed
US-20040152721-A1 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives LES LABORATOIRES SERVIER (FR) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152721-A1 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives PYM1, PNPO, IDO1 GALR3 1515/4885PRKCA 3464/4885ALDH1A1 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.